STAT6 activation in ulcerative colitis: A new target for prevention of IL-13-induced colon epithelial cell dysfunction

Inflammatory Bowel Diseases

Volumn 17, Issue 11, 2011, Pages 2224-2234

  Rosen, Michael J ^a   Frey, Mark R ^b   Washington, M Kay ^a   Chaturvedi, Rupesh ^a,c   Kuhnhein, Lindsay A ^a   Matta, Poojitha ^a   Revetta, Frank L ^a   Wilson, Keith T ^a,c   Polk, D Brent ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cell membrane permeability; interleukin 13; STAT6 transcription factor; suberoylanilide hydroxamic acid; ulcerative colitis

Indexed keywords

CLAUDIN 2; INTERLEUKIN 13; SMALL INTERFERING RNA; STAT6 PROTEIN; VORINOSTAT;

ADOLESCENT; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; COLON MUCOSA; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ULCERATIVE COLITIS;

APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELLS, CULTURED; CHILD; CLAUDINS; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; EPITHELIAL CELLS; FEMALE; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-13; MALE; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 80054760346     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21628     Document Type: Article

References (43)

1. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434. (Pubitemid 47123518)
2. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007; 56: 1696-1705. (Pubitemid 350206296)
3. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157: 1261-1270. (Pubitemid 126449643)
4. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004; 113: 1490-1497. (Pubitemid 39071705)
5. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005; 129: 550-564. (Pubitemid 41096643)
6. Hershey GK,. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003; 111: 677-690. (Pubitemid 36470232)
7. Takeda K, Kamanaka M, Tanaka T, et al. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol. 1996; 157: 3220-3222. (Pubitemid 126449129)
8. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004; 104: 543-549. (Pubitemid 38900039)
9. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002; 99: 618-626. (Pubitemid 34533100)
10. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A. 1997; 94: 13897-13902. (Pubitemid 28009681)
11. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999; 189: 1939-1946.
12. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008; 112: 1424-1433.
13. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005; 125: 1045-1052.
14. Edelblum KL, Washington MK, Koyama T, et al. Raf protects against colitis by promoting mouse colon epithelial cell survival through NF-kappaB. Gastroenterology. 2008; 135: 539-551.
15. Yu CR, Mahdi RM, Ebong S, et al. Cell proliferation and STAT6 pathways are negatively regulated in T cells by STAT1 and suppressors of cytokine signaling. J Immunol. 2004; 173: 737-746. (Pubitemid 38924247)
16. Hebenstreit D, Luft P, Schmiedlechner A, et al. SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol. 2005; 42: 295-303. (Pubitemid 39626761)
17. Weber CR, Raleigh DR, Su L, et al. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010; 285: 12037-12046.
18. Inoue S, Matsumoto T, Iida M, et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol. 1999; 94: 2441-2446. (Pubitemid 29420671)
19. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002; 17: 629-638. (Pubitemid 35351508)
20. Kadivar K, Ruchelli ED, Markowitz JE, et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis. 2004; 10: 593-598. (Pubitemid 39276467)
21. Vainer B, Nielsen OH, Hendel J, et al. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine. 2000; 12: 1531-1536.
22. Camoglio L, Te Velde AA, Tigges AJ, et al. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4: 285-290. (Pubitemid 128699868)
23. Nielsen OH, Koppen T, Rudiger N, et al. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci. 1996; 41: 1786-1793.
24. West GA, Matsuura T, Levine AD, et al. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology. 1996; 110: 1683-1695. (Pubitemid 26169204)
25. Niessner M, Volk BA,. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reverse transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995; 101: 428-435.
26. Karttunnen R, Breese EJ, Walker-Smith JA, et al. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol. 1994; 47: 1015-1018.
27. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996; 110: 1810-1819. (Pubitemid 26169219)
28. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47: 487-496.
29. Madden KB, Whitman L, Sullivan C, et al. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J Immunol. 2002; 169: 4417-4422. (Pubitemid 35178216)
30. Ceponis PJ, Botelho F, Richards CD, et al. Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J Biol Chem. 2000; 275: 29132-29137.
31. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009; 15: 283-293.
32. Gough DJ, Corlett A, Schlessinger K, et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009; 324: 1713-1716.
33. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev. 2001; 1: 194-202. (Pubitemid 33741894)
34. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev. 2006; 6: 38-51. (Pubitemid 43054973)
35. Carew JS, Giles FJ, Nawrocki ST,. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008; 269: 7-17.
36. Huang X, Guo B,. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 2006; 66: 9245-9251. (Pubitemid 44521146)
37. Klampfer L, Huang J, Shirasawa S, et al. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: the role of signal transducers and activators of transcription 1 and p21. Cancer Res. 2007; 67: 8477-8485. (Pubitemid 47437421)
38. Yuan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005; 307: 269-273. (Pubitemid 40116244)
39. Kramer OH, Knauer SK, Greiner G, et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009; 23: 223-235.
40. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol. 2006; 176: 5015-5022.
41. Glauben R, Batra A, Stroh T, et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 2008; 57: 613-622. (Pubitemid 351579973)
42. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007; 13: 1299-1307. (Pubitemid 350073591)
43. de Zoeten EF, Wang L, Sai H, et al. Expression of HDAC9 by T regulatory cells prevents colitis in mice. Gastroenterology. 2010; 138: 583-594.